Episode Details

Back to Episodes
Ep. 399 - Key themes from Jefferies. Plus: U.K. regulatory innovation

Ep. 399 - Key themes from Jefferies. Plus: U.K. regulatory innovation

Season 7 Episode 399 Published 1 day, 6 hours ago
Description

Speed to patients and cross-border collaboration dominated conversations at London Life Sciences Week, even as investors on both sides of the Atlantic grapple with the COINS Act’s restrictions on taking equity in China-based companies. In a special live edition of the BioCentury This Week podcast, recorded at the 4th Biotech CEO & Investor Reception in London, Stephen Hansen is joined by Jackie Mulryne of Morgan Lewis, WuXi AppTec co-CEO Steve Yang, and BioCentury’s Simone Fishburn and Josh Berlin to share key takeaways from the week.
The panel discusses MHRA’s push under new CEO Lawrence Tallon to make the U.K. a hub for regulatory innovation, momentum behind non-animal methods (NAMs), and why AI-driven drug design is creating surging demand for automated wet lab capacity. They also explore why European investors see little advantage from COINS, and the split in reactions to Isomorphic Labs’ reported $5 billion raise.

View full story: https://www.biocentury.com/article/661686

#LondonLifeSciencesWeek #RegulatoryInnovation #AIDrugDiscovery #COINSAct #BiotechInvesting

0:00 Introduction
2:13 U.K. Regulatory Innovation
15:10 AI Needs Wet Labs
17:56 COINS Act and Investors
24:13 Isomorphic Valuation Debate

To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com.

Reach us by sending a text

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us